Chair: Dag Aarsland, MD
Dag Aarsland, MD, is Professor and Head of Department of Old Age Psychiatry,Institute of Psychiatry, Psychology and Neuroscience at King’s College London, and Research Director at the Centre for Age-Related Medicine, Stavanger University Hospital. As a psychiatrist he has worked as a senior consultant in geriatric psychiatry for most of his career. His main research interest is the neuropsychiatric aspects of patients with neurodegenerative diseases, in particular translational studies on cognitive decline in Parkinson’s disease and dementia with Lewy bodies. He is PI of European DLB Consortium, member of the Scientific board of LBDA, Member of International DLB Consortium, PI of the Western Norwegian Dementia study and the Prodromal LBD study. He has published more than 400 papers in DLB and related areas, including clinical trials, cohort studies, and a wide range of biomarkers including imaging, CSF and EEG.
Vice Chair: Jim Leverenz
Dr. James Leverenz is neurologist and neuropathologist and currently is the Director of the Cleveland site of the Lou Ruvo Center for Brain Health and the Joseph Hahn MD Endowed Chair of the Neurological Institute at the Cleveland Clinic. His clinical and research interests are the aging-associated neurological disorders including the Lewy body dementias, Parkinson’s disease, Alzheimer’s disease, and other neurodegenerative disorders. He serves on the Scientific Advisory Council for the Lewy Body Dementia Association (LBDA) and the LBDA Research Centers of Excellence Management and Industry committees, and is on the Board of Directors and Professional Advisory Board for the Cleveland Chapter of the Alzheimer’s Association. Currently he is the principal investigator for the National Institute of Health (NIH) funded Dementia with Lewy Bodies Consortium and director of the Cleveland Alzheimer’s Disease Research Center. He is also principal- or co-investigator on additional projects funded by the Alzheimer’s Association, Alzheimer’s Drug Discovery Foundation, Department of Defense, Lewy Body Dementia Association and NIH (NIA, NINDS).
Programs Chair: Laura Bonanni
Prof. Bonanni is an Associate Professor in Neurology; Head of Dementia and Movement Disorder's Centre, Neurology Clinic, University of Chieti-Pescara, Italy. She spent significant periods of time in scientific training at first class American Institutions. Laura Bonanni has devoted her research interests to the study of pathophsyiological and diagnostic aspects of Dementia with Lewy Bodies.
Prof. Bonanni is a member of several professional societies and organisations and her leadership roles include coordinating an Italian Network on DLB which now includes 133 dementia centres making it, the largest existing network of its type. She is also on the small executive Steering Group responsible for direction of the recently formed European DLB (E-DLB) Consortium and of the recently constituted ISTAART LBD-Professional Interest Area.
Prof. Bonanni has received conspicuous National and international fundings and important scientific acknowledgments, as a visiting professorship at University of Cincinnati, Ohio, and the designation as Italian leader within the international research on DLB.
Communications Chair: Elaine Tomkinson
Elaine has 25 years in technical, operational and managerial experience in the planning, executing, reporting and publishing clinical studies in the academic setting, biotech and Pharma Industry to include global medical affairs and development. Her clinical research experience has been specifically dedicated to Oncology and HIV/AIDS indications, NeuroSciences, Pharmacology, First in Man, Ph I through IV clinical trials and a Global Expanded Access Program where she gained experience managing/leading in parallel trials and multidisciplinary trial teams in complex matrix environments. Additionally she has had the accountability and responsibility for establishing, revising departmental yearly and five yearly budget forecasting and individual project budgets to include headcount. She has demonstrated a global cross cultural ability in the establishment of strong scientific partnership with Key Opinion Leaders (KOL’s), medical advisors and business partners to optimize study design and execution of same to meet regulatory and company obligations.(China, Asia Pacific, Australia, Latin America, Middle East, EU, and USA).
Elaine has a thorough knowledge of Good Clinical Practice, clinical trial designs, regulatory and global development processes. The additional experience as the dedicated clinical submissions coordinator for an IND,NDA submission to the FDA/EMEA for a tyrosine kinase inhibitor allowed her to contribute to the quality production of the CSR’s, narratives, SCE and SCS as well as the preparation of background documents and leadership/coordination of the team.
During Elaine’s background in international senior hospital management as associate director of nursing and director of education she was responsible for leading/managing up to 500 nurses to include: adult/pediatric intensive care, surgical and outpatient arenas with 12 direct reports. As a core team member for hospital accreditation to the ISO 9000 + program she gained an intimate knowledge of continuous quality improvement (CQI), auditing and SOP writing. These skills have been applied to the development of setting up various internal quality programs to enhance study conduct and execution, compliance to GCP. Protocols and internal SOP’s to meet the demands for external auditing/monitoring from sponsor companies and health authorities with success.
Executive Committee Member: Bradley Boeve, MD
Dr. Boeve is a consultant in the Department of Neurology and Center for Sleep Medicine at Mayo Clinic in Rochester, Minnesota. He also serves as Chair of the Division of Behavioral Neurology. He holds the academic rank of Professor of Neurology, Mayo Clinic College of Medicine and Science. He is recognized with the distinction of the Little Family Foundation Professorship in Lewy Body Dementia. His clinical and research interests include the non-Alzheimer’s degenerative dementias and the neurologically-based sleep disorders, and particular interests in Lewy body dementia, frontotemporal dementia, and REM sleep behavior disorder. He is a member of the Scientific Advisory Council of the Lewy Body Dementia Association (LBDA), and coordinates the LBDA Research Centers of Excellence program. He is funded by the National Institute on Aging, National Institute of Neurological Disorders and Stroke, the Little Family Foundation, and the Mangurian Foundation. He has coauthored over 500 peer-reviewed papers and over 30 book chapters, and has co-edited 2 books.